Laekna Pharmaceutical Ningbo Co. Ltd. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Shanghai Xianxiang Medical Technology Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to an EGFR (HER1; erbB1) mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has disclosed camptothecin derivatives reported to be useful for the treatment of cancer.

Jiangsu Simcere Biologics Co. Ltd. has described bispecific antibody-drug conjugates (ADC) comprising a bispecific human antibody targeting hepatocyte growth factor receptor (HGFR; MET) and epidermal growth factor receptor (EGFR; HER1; erbB1), covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.

Signet Therapeutics Co. Ltd. has divulged transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer, metabolic disorders, inflammatory disorders and neurodegeneration.

Aché Laboratórios Farmacêuticos SA has identified compounds acting as sodium/glucose cotransporter 1 (SGLT-1), SGLT-2 and dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the treatment of cardiovascular, renal and metabolic diseases.

Laekna Pharmaceutical Ningbo Co. Ltd. has synthesized compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer.

Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and at Tongji University have disclosed glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) and glutaminyl-peptide cyclotransferase (QPCT; QC) inhibitors reported to be useful for the treatment of cancer, obesity, aging, immunological disorders and neurological disorders.

Ehrlich Biotechnology Co. Ltd. has described antibody-drug conjugates comprising an antibody targeting EGFR (HER1; erbB1) covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer.

Beijing Changping Laboratory has divulged irradiation activated platinum complex prodrugs reported to be useful for the treatment of cancer.